These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30135996)

  • 1. Lipidomic differentiation of Graves' ophthalmopathy in plasma and urine from Graves' disease patients.
    Byeon SK; Park SH; Lee JC; Hwang S; Ku CR; Shin DY; Yoon JS; Lee EJ; Moon MH
    Anal Bioanal Chem; 2018 Nov; 410(27):7121-7133. PubMed ID: 30135996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue.
    Ji DY; Park SH; Park SJ; Kim KH; Ku CR; Shin DY; Yoon JS; Lee DY; Lee EJ
    Sci Rep; 2018 Jun; 8(1):9262. PubMed ID: 29915201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry.
    Byeon SK; Lee JY; Lee JS; Moon MH
    J Chromatogr A; 2015 Feb; 1381():132-9. PubMed ID: 25597892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
    Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
    Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.
    Xia N; Zhou S; Liang Y; Xiao C; Shen H; Pan H; Deng H; Wang N; Li QQ
    Int J Mol Med; 2006 May; 17(5):911-6. PubMed ID: 16596280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS.
    Byeon SK; Kim JY; Lee JS; Moon MH
    Anal Bioanal Chem; 2016 Mar; 408(9):2265-74. PubMed ID: 26873218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
    He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
    Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causality of blood metabolites and metabolic pathways on Graves' disease and Graves' ophthalmopathy: a two-sample Mendelian randomization study.
    Wang T; Zhang Y; Wu C; Yang H; Luo Z
    Endocrine; 2024 Aug; 85(2):786-793. PubMed ID: 38448677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
    Khamisi S; Anders Karlsson F; Ljunggren Ö; Thulin M; Larsson A
    Cytokine; 2023 Sep; 169():156269. PubMed ID: 37307688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset.
    Lantz M; Planck T; Asman P; Hallengren B
    Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tear-derived exosomal biomarkers of Graves' ophthalmopathy.
    Shi TT; Zhao RX; Xin Z; Hou ZJ; Wang H; Xie RR; Li DM; Yang JK
    Front Immunol; 2022; 13():1088606. PubMed ID: 36561758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Model for Graves' Ophthalmopathy in Patients with New-Onset Graves' Disease.
    Ahn HY; Lee J; Lee JK
    Thyroid; 2022 Dec; 32(12):1559-1567. PubMed ID: 36128837
    [No Abstract]   [Full Text] [Related]  

  • 14. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
    Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
    PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of extraocular muscles in Graves' ophthalmopathy using T1 mapping.
    Zhu H; Zou M; Wu D; Li B; Su Y; Li Y; Hong S; Yang Z
    Eur Radiol; 2023 Dec; 33(12):9074-9083. PubMed ID: 37466707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
    Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
    Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy.
    Pawlowski P; Mysliwiec J; Stasiak-Barmuta A; Bakunowicz-Lazarczyk A; Gorska M
    Folia Histochem Cytobiol; 2009; 47(1):29-33. PubMed ID: 19419934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention behavior of lipids in reversed-phase ultrahigh-performance liquid chromatography-electrospray ionization mass spectrometry.
    Ovčačíková M; Lísa M; Cífková E; Holčapek M
    J Chromatogr A; 2016 Jun; 1450():76-85. PubMed ID: 27179677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of lipoprotein-specific lipids in patients with acute coronary syndrome by asymmetrical flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry.
    Lee JH; Yang JS; Lee SH; Moon MH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1099():56-63. PubMed ID: 30243114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Li HX; Xiang N; Hu WK; Jiao XL
    J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.